Elite in Eosinophilic Colitis

Dr. Marc E. Rothenberg

Pediatric Allergy and Immunology | Allergy and Immunology
3333 Burnet Ave, Mlc 2000, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Elite in Eosinophilic Colitis
3333 Burnet Ave, Mlc 2000, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marc Rothenberg is a Pediatric Allergy and Immunologist and an Allergy and Immunologist in Cincinnati, Ohio. Dr. Rothenberg is rated as an Elite provider by MediFind in the treatment of Eosinophilic Colitis. His top areas of expertise are Eosinophilic Esophagitis, Eosinophilic Enteropathy, Eosinophilic Colitis, Endoscopy, and Tissue Biopsy. Dr. Rothenberg is currently accepting new patients.

His clinical research consists of co-authoring 349 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles and participated in 2 clinical trials in the study of Eosinophilic Colitis.

Specialties
Pediatric Allergy and Immunology
Allergy and Immunology
Licenses
Allergy & Immunology in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO

Locations

3333 Burnet Ave, Mlc 2000, Cincinnati, OH 45229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EoG), Enteritis (EoN) and Colitis (EoC)
Enrollment Status: Recruiting
Publish Date: September 12, 2025
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome
A Phase 3, 52-week, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Mepolizumab SC in Participants Aged 6 to 17 Years With Hypereosinophilic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2024
Intervention Type: Drug
Study Drug: Dupilumab
Study Phase: Phase 2
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Enrollment Status: Completed
Publish Date: January 19, 2024
Intervention Type: Other, Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis
A Randomized, Double-Blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Biological
Study Drug: Benralizumab
Study Phase: Phase 2/Phase 3
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort
Enrollment Status: Completed
Publish Date: September 28, 2021
A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622
A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622
Enrollment Status: Completed
Publish Date: June 23, 2020
Intervention Type: Drug
Study Phase: Phase 3
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial
Enrollment Status: Completed
Publish Date: May 26, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

349 Total Publications

Longitudinal Enrichment of Eosinophilic Esophagitis in Children with AD: The MPAACH Cohort.
Longitudinal Enrichment of Eosinophilic Esophagitis in Children with AD: The MPAACH Cohort.
Journal: medRxiv : the preprint server for health sciences
Published: October 03, 2025
Similar Doctors
Advanced in Eosinophilic Colitis
Dr. Juan P. Abonia
Allergy and Immunology
Advanced in Eosinophilic Colitis
Dr. Juan P. Abonia
Allergy and Immunology

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4200
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Juan Abonia is an Allergy and Immunologist in Cincinnati, Ohio. Dr. Abonia is rated as a Distinguished provider by MediFind in the treatment of Eosinophilic Colitis. His top areas of expertise are Eosinophilic Esophagitis, Eosinophilic Enteropathy, Mast Cell Activation Syndrome (MCAS), Hereditary Alpha-Tryptasemia, and Endoscopy. Dr. Abonia is currently accepting new patients.

Experienced in Eosinophilic Colitis
Dr. Justin T. Schwartz
Pediatric Allergy and Immunology | Pediatrics | Allergy and Immunology
Experienced in Eosinophilic Colitis
Dr. Justin T. Schwartz
Pediatric Allergy and Immunology | Pediatrics | Allergy and Immunology
3333 Burnet Avenue, Ml 2000, 
Cincinnati, OH 
 (0.1 miles away)
513-636-6771
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Justin Schwartz is a Pediatric Allergy and Immunologist and a Pediatrics provider in Cincinnati, Ohio. Dr. Schwartz is rated as an Advanced provider by MediFind in the treatment of Eosinophilic Colitis. His top areas of expertise are Eosinophilic Esophagitis, Eosinophilic Enteropathy, Esophagitis, and Eosinophilic Asthma. Dr. Schwartz is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rothenberg's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile